1-5 of 5
David Hong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Paolo Strati, Xubin Li, Qing Deng, Lei Feng, Ryan Sun, Andrew Jallouk, Sherry Adkins, Taylor Cain, Swapna Johncy, Raphael E Steiner, Sairah Ahmed, Dai Chihara, Luis Fayad, Swaminathan Padmanabhan Iyer, Sandra B. Horowitz, Rachel Nehlsen, Loretta J. Nastoupil, Ranjit Nair, Ahmed Hassan, Taher Daoud, Misha Hawkins, Felipe Samaniego, Maria Alma Rodriguez, Elizabeth J Shpall, Partow Kebriaei, Christopher R. Flowers, David Hong, Jason Westin, Sattva S. Neelapu, Michael R. Green
Journal: Blood
Blood (2022) 140 (Supplement 1): 7493–7495.
https://doi.org/10.1182/blood-2022-157448
Published: 2022
Journal Articles

The Discover Trial: Application of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Allogeneic Stem-Cell Transplant Patients

Monica Fung, MD, Hon Seng, BS, Desiree Hollemon, MSN, MPH, David Hong, MD, Timothy Blauwkamp, PhD, Mickey Kertesz, PhD, Jamie Eng, BS, Kathy Wong, BS, Aaron C. Logan, MDPhDMPhil, Peter Chin-Hong, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1937.
https://doi.org/10.1182/blood.V130.Suppl_1.1937.1937
Published: 2017
Journal Articles

Clinical Outcomes and Factors Predicting Development of Venous Thromboembolic Complications in Patients with Advanced Refractory Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience

Apostolia-Maria Tsimberidou, MD, PhD, Sushma Vemulapalli, MD, Lakshmi Chintala, MD, Navjot Dhillon, MD, Xiudong Lei, PhD, David Hong, MD, Razelle Kurzrock, MD, Investigational Cancer Therapeutics, M.D.
Journal: Blood
Blood (2008) 112 (11): 3828.
https://doi.org/10.1182/blood.V112.11.3828.3828
Published: 2008
Journal Articles

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Paul A. Hamlin, MD, Carol Aghajanian, M.D., David Hong, M.D., Anas Younes, M.D., Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Matthew A. Spear, MD, Razelle Kurzrock, MD
Journal: Blood
Blood (2008) 112 (11): 4939.
https://doi.org/10.1182/blood.V112.11.4939.4939
Published: 2008
Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.
Journal: Blood
Blood (2007) 110 (11): 4504.
https://doi.org/10.1182/blood.V110.11.4504.4504
Published: 2007